The Medicines Company: Q2 FY 2015 Results (The Medicines Company) - Jul 30, 2015 - Anticipated data from clinical trial to affirm cholesterol efflux and efflux saturation and to assess ultrasound-measured plaque regression in Q1 2016
Anticipated clinical data • Dyslipidemia
|